TMCnet News

Pipeline Therapeutics Appoints Peter Slover as Chief Financial Officer
[October 15, 2020]

Pipeline Therapeutics Appoints Peter Slover as Chief Financial Officer


Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Peter Slover as the company's Chief Financial Officer. Mr. Slover brings more than 20 years of experience in financing strategy, and financial planning and reporting to Pipeline.

"I am delighted to welcome Pete to the Pipeline team as our Chief Financial Officer," said Carmine Stengone, President & CEO of Pipeline Therapeutics. "Pete's recent IPO experience, combined with his track record of successful financings, will serve us well as we seek to fund the continued development of our pioneering neuroregenerative drug candidates."

"I am thrilled to be joining Pipeline at such a pivotal moment in the company's development," said Peter Slover, CFO of Pipeline Therapeutics. "I believe Carmine has assembled an incredible scientific team, which is in turn positioning the company to make a major contribution to the current treatment paradigm for atients suffering from sensorineural hearing loss, as well as other neurological disorders."



Prior to becoming Pipeline Therapeutics' Chief Financial Officer, Peter previously served as Chief Financial Officer at Sophiris Bio Inc. (NASDAQ: SPHS), where he led Sophiris' initial public offering (IPO) on NASDAQ. Before that, he held a variety of significant management positions at Anadys Pharmaceuticals Inc. (NASDAQ: ANDS), including Vice President, Finance and Operations. Before joining Anadys, Peter was an auditor at KPMG LLP, where he spent seven years in public accounting.

Peter is a Certified Public Accountant in the State of California (inactive). He received a B.S. in Business Administration from Shippensburg University.


About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.


[ Back To TMCnet.com's Homepage ]